Everyday researchers face the daunting challenge of creating more effective biotherapeutics. Many candidates fail due to a lack of critical stability information that’s tightly linked to function and efficacy. Scientists deserve a technology early on in their research that reveals deep bioanalytical characterization. Prometheus quickly and precisely measures conformational and colloidal stability of any protein. Examples of optimizing storage/buffer formulation conditions and functional screening to identify better biotherapeutic targets using Prometheus will be discussed.
Most recent content
24:28Thermal stability measurements for biologics developability profiling
Learn about four methods for thermal stability measurements: DSC, CD, DSF and nanoDSF. You'll review their pros and cons, what they data tell you and why it's important for biologics developability.
22:23Selective degradation of cancer target WDR5 — Evaluation of PROTACs binary and ternary affinities with Spectral Shift
Chances are your company’s research and development pipeline includes several PROTAC candidates — placing you with many others in the race to bring successful and efficient protein degraders to the cl
8:38Explore Prometheus Panta – Frequently asked questions about stability profiling experiments
In this video, Nathan Wallace, Application Specialist at NanoTemper, addresses common questions about experimental design for developability profiling and the operation of Prometheus Panta.
20:19Explore Prometheus Panta – Biologics developability assessment with four integrated technologies
Developability assessment is a critical part of the evaluation and selection of candidates for further optimization and development for biologics researchers. This work entails collecting, ranking, an
16:42How to keep your degrader pipeline moving forward with Dianthus
The development of your protein degrader is a multi-step and complex process usually packed with challenges that if left unsolved will delay the progress of your project. What if you could overcome co
21:31How biologics teams approach developability screening of their candidates with combinatorial stability characterization
Full developability profiles de-risk the selection process for biologics candidates during early development workflows. There are many critical quality attributes to evaluate when it comes to developa
17:33How to use light scattering techniques to predict your biologic’s self-association behavior at high concentrations
Developability work requires the assessment of multiple critical quality attributes (CQAs) of your biologics. Many of these CQAs are measured or monitored using low-volume, low-concentration samples.
13:12How biologics teams use Dynamic Light Scattering to identify leading candidates
Watch this 15 min video to learn how groups in early biologics development and formulation use Dynamic Light Scattering (DLS) to make informed decisions that de-risk downstream biologics development.
25:08Overcome bottlenecks in viral vector manufacturing
The success of your gene therapy vectors is dependent on optimal formulation conditions. Finding a buffer that provides better long-term stability for AAVs is a crucial step in the process of developi
37:25Put your challenging affinity screening campaigns back on track — after you’ve tried everything else
When you’re entrusted with developing therapeutics for challenging or undruggable targets, it’s a struggle to characterize molecular interactions. And it’s not for lack of effort or expertise — SPR an
21:48How to improve outcomes of your viral vectors for gene therapy with high-quality data from biophysical profiling methods
Optimizing your vectors for gene therapy is a daunting task. When developing and optimizing AAVs, concerns such as serotype, storage stability, expression method, and genetic fill level must be addres
25:16Dynamic Light Scattering (DLS) is a technique that allows researchers to accurately size their biologic molecules and determine the distribution of particle sizes in a solution. In order to turn scatt
28:21Join Dr. Brittney Mills as she explains what criteria AbbVie’s preformulation department screens for in their antibody candidates.
14:01The desire to use technology that allows you to study membrane proteins in close-to-native conditions is specifically important when it comes to interaction measurements. It’s always a question how mu
12:06What you’ll learn It’s very common to experience low expression levels when producing membrane proteins — plus they’re finicky and unstable when they're outside of their native environment. Just know
56:52Are you working in the field of small molecule drug discovery? Join this webinar to explore the drug discovery workflow and discover tools that can help in your quest for the most promising lead com
35:47Targeted protein degradation using molecular glues or proteolysis-targeting chimeras (PROTACs) is an increasingly important therapeutic modality, especially for undruggable targets. Even with candidat
35:24Effect of different SARS-CoV-2 variants on COVID 19 assays and vaccines
SARS-CoV-2, the causative agent of COVID-19, has an ssRNA genome of almost 30kb that encodes for a total of 26 proteins. Among the four structural viral protein, in particular the S protein stands out
33:11Dr. Leah Pandiscia and Dr. Daniel Turman review how to integrate the Prometheus Panta and Monolith instruments in a characterization workflow demonstration, showing how to maximize stability and funct
22:36Hear how Dr. Sathya Venkataramani from Janssen Biotherapeutics maximized protein stability using the Prometheus in a real life case study about the design and characterization of antibody-based drugs.